Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixchiq in healthy children aged 1 to 11 years
NCT07133178Phase 3Withdrawn
- Sponsor
- Valneva
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fezolinetant in chikungunya virus infection, sponsored by Valneva. Planned start Feb 2026; status: withdrawn.
02
Drugs
fezolinetant
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT07133178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133178.